Association of Baseline Serum Soluble Tumour Necrosis Factor Receptor Levels with the Response of Rheumatoid Arthritis to Janus Kinase Inhibitor Therapy

Table 2

Univariate and multivariate logistic regression analysis for outcomes.

	OR	95% CI	p value
Univariate analysis
Age (years)	0.973	[0.942–1.010]	0.104
Female (%)	0.820	[0.231–2.910]	0.759
BMI	0.968	[0.847–1.110]	0.627
Duration (year)	0.952	[0.897–1.010]	0.110
Stage		I reference
II	0.857	[0.218–3.370]	0.825
III	0.444	[0.072–2.740]	0.382
IV	0.211	[0.036–1.220]	0.082
CRP (mg/dL)	1.070	[0.888–1.290]	0.475
SDAI	0.985	[0.942–1.030]	0.491
Biologic- and JAKinib-naïve status	1.900	[0.702–5.150]	0.206
JAKinib	Baricitinib	Reference
Tofacitinib	1.780	[0.659–4.800]	0.256
MTX use	1.640	[0.532–5.300]	0.390
PSL use	0.476	[0.176–1.290]	0.143
SASP use	0.783	[0.268-2.290]	0.654
IGU use	0.328	[0.039-2.750]	0.304
BUC use	0.436	[0.051-3.760]	0.450
TAC use	0.233	[0.029–1.910]	0.175
Log IL-6 at baseline	0.504	[0.187–1.360]	0.176
Log sIL-6R at baseline	0.213	[0.011–4.000]	0.301
Log sgp130 at baseline	0.237	[0.011–5.340]	0.365
sTNFR II/I ratio at baseline	0.808	[0.222–2.940]	0.746
Log sTNFR II at baseline	0.002	[0.0000653–0.634]	0.034
Log sTNFR I at baseline	0.013	[0.000126–1.300]	0.065
Multivariate analysis
Log sTNFR II at baseline	0.001	[0.000000251–0.458]	0.027

Abbreviations: OR: odds ratio; CI: confidence interval; BMI: body mass index; SDAI: Simplified Disease Activity Index; CRP: C-reactive protein; JAKinib: Janus kinase inhibitor; MTX: methotrexate; PSL: prednisolone; IL-6: interleukin-6; sIL-6R: soluble IL-6 receptor; sgp130: soluble gp130; sTNFR-I: soluble tissue necrosis factor receptor-I; sTNFR-II: soluble tissue necrosis factor receptor-II; SASP: salazosulfapyridine; IGU: iguratimod; BUC: bucillamine; TAC: tacrolimus.